BioWorld - Tuesday, November 26, 2024

Analysis and data insight, BioWorld
Analysis and data insight, BioWorld RSS Feed RSS

Coronavirus, question marks

Capital concerns: Coronavirus pandemic could shorten cash runways

March 30, 2020
By Peter Winter
No Comments
As the coronavirus pandemic rages on, biopharma companies are being forced to respond to multiple challenges that could derail their existing business plans. Already companies are reporting that, in therapeutic indications not involving COVID-19, their ongoing and planned clinical trials are being interrupted or delayed by the pressures now being imposed on global health care systems.
Read More
Drug pricing illustration

BioWorld Financings Reports: Cancer, neurology, endocrine take 47% of funding in 2019

March 30, 2020
By Karen Carey
No Comments
A comparison of the last three years puts 2019 on top for having brought the most money into the biopharma industry across 15 key therapeutic markets – a total of $299.78 billion vs. $284.7 billion in 2018 and $201.56 billion in 2017. The analyses includes financings tracked by BioWorld and deals and grants that are within the Cortellis database, all covering therapeutic areas included within the corresponding BioWorld Financings Reports for 2019.
Read More

Biopharmaceutical collaborations: February 2020

March 27, 2020
No Comments
Biopharma licensings, joint ventures and collaborations, including: Achaogen, Advaxis, Aimmune, Aptevo, Aradigm, Astrazeneca, Atreca, Bicycle, Biogen, Caribou, Catalent, Cellectis, Cipla, Clover, Collegium, Curis, Cytodyn, Daewoong, Dyadic, Eisai, Evotec, Eyepoint, Genentech, Glenmark, Grifols, GSK, Hanmi, Hikma, Hollister, Hummingbird, Icagen, Immunos, Innocare, Janssen, Jounce, Karuna, Karyopharm, Kissei, Ligand, Luye, Medivir, Merck, Mylan, Nanostring, Norgine, Noxopharm, Otologic, Paratek, Pfizer, Portola, Probiogen, Redhill, Roche, Sangamo, Sarepta, Tetra, Trianni, Wize, Wockhardt, Wuxi, Xencor, Zeria, Zy.
Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: February 2020

March 27, 2020
No Comments
Deals between biopharma companies and government or nonprofit entities, including: AB Biotics, ACT Genomics, Active Biotech, Active Motif, Agex, Be Cool, Benevolentai, Berg Pharma, Berkeley Lights, Beroni, Biomarin, Bridge, Cellular Biomedicine, Chugai, Cocrystal, Dianomi, Dyadic, Enochian, Entourage Phytolab, Erytech, Evgen, Exicure, FDA, Gemini, Generex, Genprex, Gibson Oncology, Gilead Sciences, GSK, Innovation, J&J, Medigen, NIH, Novartis, Oncologie, Orgenesis, Sanofi Pasteur, Sapphire, Synspira, Theratechnologies, Toa Eiyo, Tonix, VBL, Venturis, WPD.
Read More